Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSC | P53634 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 10/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817444 | 1.00 | CTSK (0.53) | CTSKCTSCALDH1A1CYP1A2TSHR | |
| SCHEMBL2819297 | 0.81 | CTSC (0.46) | CTSKCTSCCTSSCTSLCTSB | |
| SCHEMBL2819293 | 0.81 | CTSC (0.46) | CTSKCTSCCTSSCTSLCTSB | |
| SCHEMBL2818402 | 0.80 | CTSL (0.56) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2818398 | 0.80 | CTSL (0.56) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2819304 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2820627 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2820629 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2819305 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL3983249 | 0.79 | CTSK (0.51) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663958-B1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-7737300-B2 | Processes and intermediates preparing cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7547701-B2 | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080114175-A1 | Processes and Intermediates Preparing Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-05-15 | — | — | US | disclosed |
| EP-1663958-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005028429-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | CTSF, CTSS, CTSE | CTSK 7/4885CTSC 15/4885ALDH1A1 1944/4885 |
| US-20080114175-A1 | Processes and Intermediates Preparing Cysteine Protease Inhibitors | SPINT2, PREP, CPN1 | CTSK 91/4885CTSC 15/4885ALDH1A1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.